M.E. Allison & CO. Inc. Takes $314,000 Position in GSK plc (NYSE:GSK)

M.E. Allison & CO. Inc. acquired a new position in GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,286 shares of the pharmaceutical company’s stock, valued at approximately $314,000.

Other hedge funds also recently bought and sold shares of the company. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 303 shares during the period. Mesirow Financial Investment Management Inc. increased its stake in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after purchasing an additional 332 shares during the period. Finally, Investment Partners Asset Management Inc. raised its position in shares of GSK by 2.3% during the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock valued at $636,000 after purchasing an additional 344 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of analyst reports. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $33.46 on Monday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The stock’s fifty day moving average price is $34.02 and its 200-day moving average price is $37.98. The firm has a market cap of $69.34 billion, a P/E ratio of 21.72, a P/E/G ratio of 1.44 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. GSK’s payout ratio is 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.